InMed Pharmaceuticals Inc.
InMed Pharmaceuticals develops small molecule CB1/CB2 receptor antagonists for Alzheimer's disease, ocular, and dermatological indications.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 16Latest story
November 2026
July 2026
InMed Pharmaceuticals develops small molecule CB1/CB2 receptor antagonists for Alzheimer's disease, ocular, and dermatological indications.
November 2026
July 2026